Secura Bio Inc., of Henderson, Nev., said it acquired global rights to histone deacetylase inhibitor Farydak (panobinostat) from Novartis AG, of Basel, Switzerland. In 2015, Farydak received FDA accelerated approval and EMA approval to treat multiple myeloma. Financial terms were not disclosed.